{"doi":"10.1016/j.esmoop.2021.100079","title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study","abstract":"BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. We determined the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of VAN + EV in patients with advanced solid cancers and the effect of combination therapy on cancer cell proliferation and intracellular pathways. PATIENTS AND METHODS: Patients with refractory solid tumors were enrolled in a phase I dose-escalation trial testing VAN (100-300 mg orally daily) + EV (2.5-10 mg orally daily). Objective responses were evaluated using RECIST v1.1. RET mutant cancer cell lines were used in cell-based studies. RESULTS: Among 80 patients enrolled, 72 (90%) patients were evaluable: 7 achieved partial response (PR) (10%) and 37 had stable disease (SD) (51%; duration range: 1-27 cycles). Clinical benefit (SD or PR ≥ 6 months) was observed in 26 evaluable patients [36%, 95% confidence intervals (CI) (25% to 49%)]. In 80 patients, median overall survival (OS) was 10.5 months [95% CI (8.5-16.1)] and median progression-free survival (PFS) 4.1 months [95% CI (3.4-7.3)]. Six patients (7.5%) experienced DLTs and 20 (25%) required dose modifications. VAN + EV was safe, with fatigue, rash, diarrhea, and mucositis being the most common toxicities. In cell-based studies, combination therapy was superior to monotherapy at inhibiting cancer cell proliferation and intracellular signaling. CONCLUSIONS: The MTDs and RP2Ds of VAN + EV are 300 mg and 10 mg, respectively. VAN + EV combination is safe and active in refractory solid tumors. Further investigation is warranted in RET pathway aberrant tumors.","journal":"ESMO Open","year":2021,"id":190720,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9568,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":755034,"name":"Ruth Sacks","orcid":"0000-0002-7181-3135","position":1,"is_corresponding":false},{"id":437265,"name":"Ishwaria M. Subbiah","orcid":"0000-0002-0758-7911","position":2,"is_corresponding":false},{"id":755035,"name":"Neele Drobnitzky","orcid":"0000-0002-3181-941X","position":3,"is_corresponding":false},{"id":258839,"name":"Sarina A. Piha‐Paul","orcid":"0000-0001-9455-1660","position":4,"is_corresponding":false},{"id":107725,"name":"David S. Hong","orcid":"0000-0001-8721-1609","position":5,"is_corresponding":false},{"id":236013,"name":"Kenneth R. Hess","orcid":"0000-0003-1377-6070","position":6,"is_corresponding":false},{"id":404730,"name":"Behrang Amini","orcid":"0000-0002-4962-3466","position":7,"is_corresponding":false},{"id":755553,"name":"Trilok Bhatt","orcid":null,"position":8,"is_corresponding":false},{"id":241553,"name":"Siqing Fu","orcid":"0000-0002-1933-0419","position":9,"is_corresponding":false},{"id":266105,"name":"Aung Naing","orcid":"0000-0002-4803-8513","position":10,"is_corresponding":false},{"id":266117,"name":"Filip Jankú","orcid":"0000-0002-8123-4065","position":11,"is_corresponding":false},{"id":266107,"name":"Daniel D. Karp","orcid":"0000-0002-5017-328X","position":12,"is_corresponding":false},{"id":58534,"name":"Gerald S. Falchook","orcid":"0000-0001-9165-2191","position":13,"is_corresponding":false},{"id":740937,"name":"Anthony P. Conley","orcid":"0000-0002-6232-1163","position":14,"is_corresponding":false},{"id":55868,"name":"Steven I. Sherman","orcid":"0000-0002-3079-5153","position":15,"is_corresponding":false},{"id":70220,"name":"Funda Meric‐Bernstam","orcid":"0000-0001-6816-6072","position":16,"is_corresponding":false},{"id":678548,"name":"Anderson J. Ryan","orcid":"0000-0001-6241-7969","position":17,"is_corresponding":false},{"id":227923,"name":"John V. Heymach","orcid":"0000-0001-9068-8942","position":18,"is_corresponding":false},{"id":226642,"name":"Vivek Subbiah","orcid":"0000-0002-6064-6837","position":19,"is_corresponding":false},{"id":227920,"name":"Tina Cascone","orcid":"0000-0003-3008-5407","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:49:26.966524Z","pmid":"33721621","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}